Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Pardes Biosciences Q4 EPS $(0.41) Beats $(0.50) Estimate

Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.50) by 18 percent. This is a 26.79 percent increase over losses of $(0.56) per share from
byBenzinga Newsdesk
March 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Pardes Biosciences (NASDAQ:PRDS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.50) by 18 percent. This is a 26.79 percent increase over losses of $(0.56) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

TransMedics Stock Skyrockets, Analysts Call It ‘One Of The Best Organic Growth Stories’

By Vandana Singh
May 1, 1:13 PM
TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-$400 million. Analysts hail TransMedics' organic growth and strong market position, praising its innovative solutions and promising prospects.

TMDX